Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn dealUK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, Share XLilly buys into MiNA’s protein-boosting RNA tech in $1.25bn dealhttps://pharmaphorum.com/news/lilly-buys-into-minas-protein-boosting-rna-tech-in-1-25bn-deal/
Vertex eyes controllable genetic drugs with $1.3bn Obsidian allianceVertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Share XVertex eyes controllable genetic drugs with $1.3bn Obsidian alliancehttps://pharmaphorum.com/news/vertex-eyes-controllable-genetic-drugs-with-1-3bn-obsidian-alliance/
Novartis expands in radio-oncology again with $1.3bn Artios allianceIn its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus Share XNovartis expands in radio-oncology again with $1.3bn Artios alliancehttps://pharmaphorum.com/news/novartis-expands-in-radio-oncology-again-with-1-3bn-artios-alliance/
Lilly cuts a $960m deal with Rigel on RIP kinaseEli Lilly has become the latest drugmaker to have a go at developing RIP kinase inhibitors, a new Share XLilly cuts a $960m deal with Rigel on RIP kinasehttps://pharmaphorum.com/news/lilly-cuts-a-960m-deal-with-rigel-on-rip-kinase/
Roche and PatchAi partner on digital tool for cancer patientsRoche’s Italian subsidiary has joined forces with digital health startup PatchAi to roll out an app that aims Share XRoche and PatchAi partner on digital tool for cancer patientshttps://pharmaphorum.com/news/roche-and-patchai-partner-on-digital-tool-for-cancer-patients/
Lilly bolts on cancer bispecifics with $1.6bn Merus allianceAlways a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes Share XLilly bolts on cancer bispecifics with $1.6bn Merus alliancehttps://pharmaphorum.com/news/lilly-bolts-on-cancer-bispecifics-with-1-6bn-merus-alliance/
Takeda signs $882m rare disease alliance with Oxford biotech EvoxEvox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, Share XTakeda signs $882m rare disease alliance with Oxford biotech Evoxhttps://pharmaphorum.com/news/takeda-signs-882m-rare-disease-alliance-with-oxford-biotech-evox/
Sosei Heptares bags another big partnership, this time with TakedaJapanese biotech Sosei’s buyout of the UK’s Heptares four years ago has rewarded it with a string of Share XSosei Heptares bags another big partnership, this time with Takedahttps://pharmaphorum.com/news/sosei-heptares-bags-another-big-partnership-this-time-with-takeda/
Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOGenmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody Share XDenmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOhttps://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/
